Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato Loxapine for Inhalation in Schizophrenic Patients With Agitation

Next Previous
X
Search
Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato Loxapine for Inhalation in Schizophrenic Patients With Agitation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Loxapine (Primary)
  • Indications Agitation; Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Alexza Pharmaceuticals

    • Most Recent Events

    • 10 Oct 2016 According to Alexza Pharmaceuticals media release, US FDA approval of ADASUVE was based on clinical efficacy data of this and another pivotal trial.
    • 14 Dec 2012 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for Staccato loxapine based on results from this and the other pivotal trial as reported in an Alexza Pharmaceuticals media release.
    • 24 Jan 2011 Results of this trial published in the British Journal of Psychiatry, according to an Alexza Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top